ActivBiotics' Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million

07-Apr-2008 - Joseph F. Finn, Jr., CPA, the Assignee for the Benefit of Creditors of ActivBiotics, announced the completion of the sale of ActivBiotics intellectual property assets for $3.5 million. The assets consisted of 1) Rifalazil, a Phase II antibiotic, 2) a library of novel rifamycin compounds, and 3) a ...

ActivBiotics Set to Sell Proprietary Assets, Including Drug Product Candidates

10-Mar-2008 - Joseph F. Finn, Jr., CPA, the Assignee for the Benefit of Creditors of ActivBiotics, confirmed that the sale of ActivBiotics' proprietary assets will be carried out through a sealed bid at 12:00 PM on March 14, 2008. There has been substantial interest from various parties about different aspects ...

ActivBiotics, Inc. Appoints Steven C. Gilman Chairman and CEO

03-May-2007 - ActivBiotics, Inc. announced that its board of directors has appointed Steven C. Gilman, Ph.D. as chairman and chief executive officer. Dr. Gilman was previously the company's president and chief executive officer. Dr. Gilman joined ActivBiotics in March 2004 as president and chief executive ...

ActivBiotics and Metaphore Complete Merger Creating Late-Stage Company Addressing Serious Infections and Inflammation

13-Jan-2006 - ActivBiotics, Inc. and Metaphore Pharmaceuticals, Inc. announced that stockholder approval of the previously announced merger has been received and the merger is now complete. The merger creates a late-stage company with two clinical stage compounds and a robust pipeline of preclinical ...

ActivBiotics, Inc. and Metaphore Pharmaceuticals, Inc. Sign Definitive Merger Agreement

Combined Company to Focus on Significant Infectious Disease and Inflammation Markets

16-Dec-2005 - ActivBiotics, Inc. and Metaphore Pharmaceuticals, Inc. announced that the two private companies have signed a definitive merger agreement. The transaction, if completed, will result in Metaphore becoming a wholly owned subsidiary of ActivBiotics. The proposed merger is subject to approval of the ...